StocksMedium•7 October 2026•
1 min read
Halozyme Wins Injunction Against Merck's Keytruda SC in European Markets
Key Facts
1The specialized Dutch patent court of the Hague found Merck to be infringing on a Halozyme MDASE patent.
2The injunction prohibits manufacturing and sale of Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands.
The specialized Dutch patent court of the Hague found Merck to be infringing on a Halozyme MDASE patent. According to a PR Newswire report, the court issued an injunction prohibiting the manufacturing, sale, and distribution of Keytruda SC in eight European countries, including France, Italy, and the Netherlands.
HALO closed at $109.72 on October 6, 2026, while MRK closed at $141.93 on the same date. The ruling disrupts Merck's commercialization of the subcutaneous version of its flagship drug in major European hubs, marking a significant legal victory for Halozyme in protecting its intellectual property.